The FDA approved Eli Lilly’s oral obesity pill orforglipron, branded Foundayo, clearing a fast-track path under the commissioner’s National Priority Review voucher program. The approval sets up direct commercial competition with Novo Nordisk’s oral Wegovy, following Novo’s earlier launch of its pill. The reporting highlights a pricing and market-access battle that will likely shape uptake as much as efficacy comparisons—particularly because the two oral products are not based on head-to-head trials. Lilly’s differentiation includes dosing convenience, while Novo is positioning its oral product as offering greater weight loss based on separate analyses. For biotech and pharma, the development is a forcing function for payer strategy, telehealth channel access, and ongoing competitive pipeline design as oral incretin therapies attempt to scale beyond injections.